| Literature DB >> 29629171 |
Min-Jing Cheng1,2, Jia-Qing Cao1, Xin-Yi Yang3, Li-Ping Zhong2, Li-Jun Hu2, Xi Lu3, Bao-Long Hou2, Ya-Jian Hu2, Ying Wang1, Xue-Fu You3, Lei Wang1, Wen-Cai Ye1, Chuang-Chuang Li2.
Abstract
Herein, we describe a concise catalytic approach to the first asymmetric total syntheses of myrtucommuacetalone, myrtucommuacetalone B, and callistrilones A, C, D and E. The syntheses proceed in only 5-7 steps from the readily available compound 11, without the need for protecting groups. Key features of the syntheses include a unique organocatalytic asymmetric Friedel-Crafts-type Michael addition with high enantioselectivity and a broad substrate scope, a novel Michael-ketalization-annulation cascade reaction, and an oxidative [3 + 2] cycloaddition. Furthermore, the new compound 7 exhibited potent antibacterial activities against several multidrug-resistant strains (MRSA, VISA and VRE), and showed greater potency than vancomycin.Entities:
Year: 2017 PMID: 29629171 PMCID: PMC5875087 DOI: 10.1039/c7sc04672c
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Representative polycyclic polymethylated phloroglucinols.
Fig. 2Retrosynthetic analysis of PPPs 2–7.
Scheme 1Asymmetric syntheses of 2 and 3.
The optimization of enantioselective FCM additions
|
| |||||||
| Entry | Catalyst | Additive |
| Solvent | Time | Yield |
|
| 1 | ( | –40 | Toluene | 24 h | 35 | 82.5 : 17.5 | |
| 2 | ( | –40–26 | Toluene | 24 h | 73 | 50 : 50 | |
| 3 | ( | –40 | Toluene | 24 h | Trace | — | |
| 4 | ( | –40 | Toluene | 24 h | Trace | — | |
| 5 | ( | –40 | Toluene | 24 h | 18 | 52.5 : 47.5 | |
| 6 | ( | –40 | Toluene | 24 h | 24 | 55 : 45 | |
| 7 | ( | –40 | Toluene | 24 h | 30 | 40 : 60 | |
| 8 | ( | –40 | Toluene | 24 h | 36 | 60 : 40 | |
| 9 | ( | –40 | Toluene | 24 h | Trace | — | |
| 10 | ( | –40 | Toluene | 24 h | 23 | 62 : 38 | |
| 11 | ( | –40 | Toluene | 24 h | 21 | 0 | |
| 12 | ( | –40 | Toluene | 24 h | Trace | — | |
| 13 | ( | –40 | Toluene | 24 h | 25 | 64 : 36 | |
| 14 | ( | –40 | Toluene | 24 h | 18 | 50 : 50 | |
| 15 | ( | –40 | Toluene | 24 h | 73 | 88 : 12 | |
| 16 | ( | –60 | Toluene | 108 h | 76 | 91 : 09 | |
| 17 | ( | –60 | DCM | 108 h | 70 | 89.5 : 10.5 | |
| 18 | ( | –60 | CHCl3 | 108 h | 30 | 91 : 09 | |
| 19 | ( | –60 | Toluene | 108 h | 74 | 92 : 08 | |
| 20 | ( | MgF2 (10%) | –60 | Toluene | 108 h | 76 | 93 : 07 |
| 22 | ( | Fe(OTf)3 (10%) | –60 | Toluene | 108 h | 74 | 91 : 09 |
| 23 | ( | Zn(OTf)2 (10%) | –60 | Toluene | 108 h | 72 | 92.5 : 7.5 |
| 24 | ( | AIF3 (10%) | –60 | Toluene | 72 h | 71 | 93.5 : 6.5 |
| 25 | ( | CaF2 (10%) | –60 | Toluene | 72 h | 74 | 92.5 : 7.5 |
| 26 | ( | AlF3 (10%) | –76 | Toluene | 7 d | 55 | 95.5 : 4.5 |
| 27 | ( | AlF3 (10%) | –76 | Toluene | 6 d | 25 | 96.5 : 3.5 |
| 28 | ( | AlF3 (10%) | –76 | Toluene | 6 d | 28 | 96 : 04 |
| 29 | ( | AIF3 (100%) | –70 | Toluene | 6 d | 77 | 95 : 05 |
| 30 | ( | AIF3 (100%) | –70 | Toluene | 6 d | 76 | 5 : 95 |
| 31 | ( | AlF3 (100%) | –70 | Toluene | 6 d | 75 | 95 : 5 (99.5 : 0.5) |
| 32 | ( | AlF3 (100%) | –70 | Toluene | 6 d | 75 | 5 : 95 (0.5 : 99.5) |
Unless otherwise stated, the reactions of entries 1–30 were performed with 11 (0.1 mmol), 12 (0.2 mmol) and CPA (0.01 mmol) in toluene (2 mL) at –76 °C to 26 °C.
Isolated yield.
Determined by chiral HPLC analysis with a ChiralCel OD-H column (i-PrOH/n-hexane = 5 : 95, 0.8 mL min–1).
4 Å MS (35 mg) was added.
3 Å MS (35 mg) was added.
5 Å MS (35 mg) was added.
The reactions of entries 31 and 32 were performed with 11 (2.0 g, 10.2 mmol), 12 (20.4 mmol) and (S)-C15 or (R)-C16 (1.02 mmol) in toluene (204 mL) at –70 °C.
The er could be easily improved by recrystallization.
Substrate scope of the enantioselective FCM additions
|
|
The er could be easily improved by recrystallization.
Scheme 2Asymmetric synthesis of PPPs 4–7.
Antibacterial activities of 2–7 and vancomycin against six Gram-positive bacterial strains (MIC, μg mL–1)
| Compound |
|
|
|
|
|
|
|
| 8 | 8 | 64 | 8 | 64 | 16 |
|
| 16 | 16 | >128 | 16 | >128 | >128 |
|
| 32 | 32 | 64 | 32 | 64 | >128 |
|
| >128 | >128 | >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 | >128 | >128 |
|
| 0.25 | 0.25 | 0.5 | 0.25 | 2 | 2 |
| Vancomycin | 2 | 8 | >128 | 1 | 4 | 2 |